NCT00744354

Vorinostat, Bortezomib, and Doxorubicin Hydrochloride Liposome in Treating Patients With Relapsed or Refractory Multiple Myeloma

A Phase 1 Dose Escalation Study of Bortezomib (Velcade®), Pegylated Liposomal Doxorubicin (Doxil®), and Vorinostat (Suberoylanilide Hydromaxic Acid, Saha, Zolinzatm) in Patients With Relapse/Refractory Multiple Myeloma

• Status: Terminated
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 32 (actual)
• Sponsor: UNC Lineberger Comprehensive Cancer Center · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

RATIONALE: Vorinostat and bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Bortezomib may also stop the growth of multiple myeloma by blocking blood flow to the tumor. Drugs used in chemotherapy, such as doxorubicin hydrochloride liposome, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving doxorubicin hydrochloride liposome together with vorinostat and bortezomib may kill more cancer cells. PURPOSE: This phase I trial is studying the side effects and best dose of vorinostat and to see how well it works when given together with bortezomib and doxorubicin hydrochloride liposome in treating patients with relapsed or refractory multiple myeloma.

Detailed description

OBJECTIVES: Primary * To determine the maximum tolerated dose of vorinostat when added to the standard regimen of bortezomib and pegylated liposomal doxorubicin hydrochloride in patients with relapsed or refractory multiple myeloma. * To identify the dose-limiting toxicities of this regimen in these patients. Secondary * To gain preliminary evidence of antitumor activity of this regimen in these patients. * To assess the degree of proteasome inhibition achieved with this regimen in these patients. * To evaluate the accumulation of acetylated alpha-tubulin after treatment with vorinostat. * To evaluate overall survival, time to progression, and progression-free survival of patients treated with this regimen. OUTLINE: This is a multicenter, dose escalation study of vorinostat. Patients receive oral vorinostat once daily on days 1,2; 4,5; 8, 9; 11, 12; bortezomib IV on days 1, 4, 8, and 11, and pegylated liposomal doxorubicin hydrochloride IV on day 4. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Blood samples are collected periodically for proteasome inhibition assays and acetylated alpha-tubulin studies. After completion of study treatment, patients are followed at 1 and 3 months.

Conditions

• Multiple Myeloma and Plasma Cell Neoplasm

Interventions

Type	Name	Description
DRUG	bortezomib	Intravenous Push 1.3 mg/m2 Days 1, 4, 8, and 11
DRUG	pegylated liposomal doxorubicin hydrochloride	Intravenous infusion, 30mg/m2, Day 4, each cycle
DRUG	vorinostat	Oral, 300mg, Days 1, 2, 4, 5, 8, 9, 11, 12, every cycle.

Timeline

• Start date: 2008-10-01
• Primary completion: 2011-12-01
• Completion: 2015-04-01
• First posted: 2008-09-01
• Last updated: 2018-01-18

Locations

4 sites across 1 country: United States